Seres Therapeutics (MCRB) Price to FCF (2015 - 2026)

Seres Therapeutics has disclosed Price to FCF across 12 years of filings, most recently posting 3.46 for Q2 2026.

• In Q2 2026, Price to FCF rose 52.12% year-over-year to 3.46; the TTM figure through Jun 2026 stood at 1.51 (up 6.17% YoY), while the FY2025 annual figure was 164.39, up 17136.12% from the prior year.
• Price to FCF came in at 3.46 for Q2 2026 at Seres Therapeutics, up from 5.2 in the prior quarter.
• In the past five years, Price to FCF ranged from a high of 76.72 in Q3 2025 to a low of 13.13 in Q3 2022.
• Average Price to FCF over 5 years is 0.45, with a median of 4.82 recorded in 2024.
• Year-over-year, Price to FCF plunged 354.0% in 2022 and jumped 1758.64% in 2025.
• Over 5 years, Price to FCF stood at 12.44 in 2022, then jumped by 68.59% to 3.91 in 2023, then increased by 5.6% to 3.69 in 2024, then sank by 161.53% to 9.65 in 2025, then jumped by 64.11% to 3.46 in 2026.
• Per Business Quant data, the three most recent Price to FCF figures were 3.46 in Q2 2026, 5.2 in Q1 2026, and 9.65 in Q4 2025.